NCT06646146Completed
Study on the Efficacy of Autologous Fat Grafting in Improving Hair Transplantation Outcomes for Patients With Localized Scleroderma-Related Alopecia
A Single-Center, Prospective, Randomized Controlled Clinical Study on the Efficacy of Autologous Fat Grafting in Improving Hair Transplantation Outcomes for Patients With Localized Scleroderma-Related Alopecia
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
Investigating the efficacy and safety of autologous fat grafting combined with hair transplantation for the treatment of hair loss in patients with localized scleroderma."
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 16 Oct 2024
- Start date
- 5 Dec 2024
- Primary completion date
- 3 Sept 2026
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT06646146
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 5 Dec 2024 to the primary completion date, 3 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received new vasodilator or immunosuppressive drug treatment within the past 3 months.
- Applied topical ointments to the surgical area within the past 2 weeks.
Other illness
- Infection of the scalp soft tissue.
- Suffering from psychiatric disorders, hematologic diseases, immune deficiencies, abnormalities in liver or kidney function, severe hypertension, severe diabetes, and other contraindications for surgery.
- Positive for HIV, HBV, HCV, HTLV-1 or -2, or syphilis.
- Patients with a history of tumor formation in the last 5 years.
Other
- Hair loss area exceeds one-third of the scalp.
- Women who are pregnant or breastfeeding.
- BMI is less than 17, making it impossible to obtain sufficient fat.
- Patients with a prednisolone intake greater than 10 mg/day. Patients deemed unsuitable for participation in this trial by the investigator's judgment.
Who the study is looking for
- 1\. Patients with clinical symptoms consistent with localized scleroderma (LoSCAT score can be used to assist in diagnosis).
- 2\. Diagnosed with secondary alopecia caused by localized scleroderma. 3. A history of hair loss in the affected area for more than 6 months, with an adequate supply of donor hair.
- 4\. The disease is inactive and has been in a stationary phase for over a year (patients have no ongoing or intermittent hair loss accompanied by local pain, itching, or burning; scalp biopsy indicates no inflammatory cell infiltration, hair follicle orifices have disappeared, and hair follicles are replaced by connective tissue).
- 5\. The general condition is stable, and the patient can tolerate anesthesia and surgery.
- 6\. BMI is greater than or equal to 17. 7. Age between 18 and 59. 8. The subject and their family are willing and able to comply with postoperative care and follow-up requirements.
- 9\. The subject and their family have given informed consent and have signed the informed consent form.
Age in the registry: 18 years to 59 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.